All In Biotech

NDA 021462 · Lilly

Alimta

Pemetrexed Disodium · Intravenous

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Aug 31, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Feb 4, 2004

Approved uses

9

Original approval plus efficacy supplements

Registered trials

1,474

328 Phase 3, 251 recruiting

FAERS reports

16,927

15,517 serious, 3,495 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 19, 2023.

ALIMTA ® is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 ) Limitations of Use: ALIMTA is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. ( 1.1 ) initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. ( 1.2 ) 1.1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) ALIMTA ® is indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC...

Mechanism: ALIMTA is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ALIMTA · PEMETREXED DISODIUM EQ 500MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
  • ALIMTA · PEMETREXED DISODIUM EQ 100MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Pemetrexed Disodium" as an intervention, any sponsor and status, largest first.

All 1,474 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • malignant neoplasm progression1,432
  • off label use1,238
  • death939
  • nausea915
  • anaemia873
  • diarrhoea851
  • pancytopenia821
  • neutropenia729
  • fatigue727
  • thrombocytopenia685
  • rash681
  • dyspnoea670

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004131
2005406
2006368
2007296
2008279
2009469
2010624
2011658
2012952
2013541
2014585
20151,671
2016556
2017736
2018958
20191,371
20201,268
20211,128
2022873
2023691
2024840
2025866
2026660

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Alimta (Pemetrexed Disodium)

2024 spending

$728K

Beneficiaries

27

110 claims

Per beneficiary

$26,956

$1,382.15 per unit

View as table
YearSpending
2020$9,697,563
2021$9,849,598
2022$7,434,149
2023$2,107,224
2024$727,804

Part B: Alimta* (Pemetrexed Disodium*) · HCPCS J9305

2024 spending

$23.0M

Beneficiaries

13,143

57,657 claims

Per beneficiary

$1,753

2024 ASP limit $4.54 per unit

View as table
YearSpending
2020$498,510,123
2021$477,381,476
2022$446,004,779
2023$80,574,519
2024$23,045,559

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 34 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.